One Shot, Months of Control: China's 'Hypertension Vaccine' Heads Into Phase Two
A Wuhan biotech firm's 'hypertension vaccine' has cleared its first-in-human trial and will move into Phase II, promising months of blood-pressure control from a few injections a year — a prospect aimed at China's 330 million hypertension patients.
For most of China's more than 330 million hypertension patients, the routine is pills, every day, for life — and not to be stopped even when the readings look fine. A Wuhan biotechnology firm is proposing a different regimen: a few injections a year.
On September 9, Wuhan Huajiyuan Biotechnology announced that its "hypertension vaccine," HJY-ATRQβ-001, had reached the preset endpoint of its Phase I trial and will advance into Phase II studies. By the account circulating on Baidu's board alongside the Weibo hashtag, it is one of the most advanced candidates of its kind anywhere, and no approved product exists yet in the world.
The name misleads, and that is doing real work in the discussion. This is a therapeutic vaccine, not a preventive one: it borrows the technology of vaccination to prompt the immune system to produce antibodies that lower blood pressure. Those antibodies persist in the body long enough for the effect to hold for months, which is the entire point — a treatment that does not depend on the patient remembering a pill every morning.
Adherence is the problem the shot is aimed at. Hypertension is China's most common chronic disease — more than one adult in four has it — and most patients with the primary form are told they will take medication indefinitely. "For hypertension patients, needing only a few injections a year would solve the problem of poor compliance, and their blood-pressure control would improve substantially, reducing the risk of stroke or heart attack," said Zhang Yi, a cardiologist at Shanghai's Tenth People's Hospital, affiliated with Tongji University, in the report that spread the news.
The trending hashtag — "the blood-pressure vaccine is coming" — showed how much explaining the concept still needs. "If it can't prevent anything in healthy people, how is this even a vaccine?" one user asked, before concluding that he would obediently stick with his quick-acting heart pills rather than try something new. Others drifted straight past the science into diet lectures about hidden sugar and salt, a reminder that for much of the audience the appeal is less the injection itself than the hope of not having to think about blood pressure every single day.
Phase II is early, and a pharmacy shelf is still years away; the antibodies' long-duration effect has to be proven at scale before any regulator will look at it. But the direction of travel explains the excitement: a treatment that shifts chronic-disease management from daily willpower to the immune system, aimed at the condition that puts more Chinese into hospitals than any other.